(18F)DCFPyL
(18F)DCFPyL Uses, Dosage, Side Effects, Food Interaction and all others data.
Prostate cancer is the most common non-cutaneous malignancy affecting men in North America - despite this, an ongoing challenge in prostate cancer therapy is the difficulty in imaging the extent and location of tumor metastases and recurrences. The images generated by positron emission tomography (PET) are less detailed than those obtained via MRI or CT, but are more sensitive and can reveal cancerous tissue in any area of the body provided the tissue is expressing the appropriate target protein. Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein expressed in many tissues that plays a role in folate uptake and neurotransmitter release - it is expressed in the prostate at levels roughly 1000-fold greater than elsewhere in the body, and even higher in prostate cancer tissue. As such, it has become a desirable target for PET imaging of prostate cancer tissues.
Piflufolastat F18, also called [F-18]-DCFPyL, is a urea-based radiopharmaceutical that binds to PSMA and allows for the visualization of cancerous prostate tissue. It was first approved by the FDA in May 2021 under the brand name Pylarify and aims to allow for earlier and more accurate detection of suspected prostate cancer metastases or recurrences.
| Trade Name | (18F)DCFPyL |
| Generic | Piflufolastat F 18 |
| Piflufolastat F 18 Other Names | (18F)DCFPyL, [F-18]-DCFPyL, 18F-DCFPyL, DCFPyL F-18, Piflufolastat F 18, Piflufolastat F-18, PyL |
| Type | |
| Formula | C18H23FN4O8 |
| Weight | Average: 441.403 Monoisotopic: 441.152526384 |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
(18F)DCFPyL is a radiopharmaceutical diagnostic agent used with PET to image PSMA-positive lesions for the diagnosis of metastatic or recurrent prostate cancer.
Piflufolastat F18 is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer who have suspected metastases and are candidates for initial definitive therapy and for men with a suspected recurrence of prostate cancer based on elevated prostate-specific antigen (PSA) levels.
(18F)DCFPyL is also used to associated treatment for these conditions: Prostate Cancer, Recurrent Prostate Cancer
How (18F)DCFPyL works
Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that plays a role in dietary folate uptake and the release of neurotransmitters within the brain. While PSMA is expressed in many tissues, its expression levels in the prostate are roughly 1000-fold greater than elsewhere in the body and even higher in prostate cancer tissue.
Piflufolastat F18 binds to PSMA and therefore, in combination with PET imaging, allows for the visualization of PSMA-positive lesions associated with prostate cancer.
Toxicity
There are no data regarding the effects of overdosage with piflufolastat F18. In the event of overdose, the amount of absorbed radiation can be mitigated by administered fluids and encouraging frequent bladder voiding. The use of diuretics to encourage voiding may also be considered.
Food Interaction
No interactions found.Volume of Distribution
Within 60 minutes of intravenous administration, piflufolastat F18 distributes to the kidneys, liver, and lungs.
Half Life
The half-life of distribution of piflufolastat F18 is 0.17 ± 0.044 hours and its elimination half-life is 3.47 ± 0.49 hours.
Elimination Route
Piflufolastat F18 is eliminated via urinary excretion - within 8 hours of intravenous administration, approximately 50% of an administered dose is excreted in the urine.
Innovators Monograph
You find simplified version here (18F)DCFPyL
